Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?

Gemcioğlu, Emin; Davutoğlu, Mehmet; Ozdemir, Ese Ece; Erden, Abdülsamet

doi:10.1016/j.msard.2020.102196

Cited by 22 publications

(24 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Significant differences in outcomes suggest that IFN might be an effective therapeutic agent for SARS‐CoV‐2 31 . The efficacy of IFN‐I against COVID‐19 was further supported in a case study 32 …”

Section: Clinical Studies Of Ifn‐i For Covid‐19mentioning

confidence: 80%

See 1 more Smart Citation

Type I interferon: From innate response to treatment for COVID‐19

Lin¹,

Shen

2020

Pediatric Investigation

View full text Add to dashboard Cite

Effective prophylactic and therapeutic interventions are urgently needed to address the coronavirus disease 2019 (COVID‐19) pandemic. Various antiviral drugs have recently been tested. Type I interferon (IFN) is a regulatory protein involved in the innate immune response, with broad‐spectrum antiviral activities and the ability to directly block viral replication and support the immune response to eliminate virus infection. Insufficient virus‐induced type I IFN production is characteristic of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, because SARS‐CoV‐2 suppresses the IFN response by interacting with essential IFN signaling pathways. Exogenous type I IFN is recommended for treating COVID‐19. Unexpectedly however, angiotensin converting enzyme‐2 (ACE2) receptor, which acts as a SARS‐CoV‐2 receptor, was shown to be stimulated by IFN, raising doubts about the suitability of IFN use. However, further studies have excluded concerns regarding IFN administration. Type I IFNs, including IFN‐α1b, have been used clinically as antiviral drugs for many years and have shown strong antiviral activity against SARS‐CoV‐2 in vitro . Preliminary clinical studies of type I IFNs, especially when delivered via aerosol inhalation, have demonstrated efficacy for the treatment and prevention of COVID‐19. Randomized controlled trials of IFN for COVID‐19 treatment are ongoing.

show abstract

Section: Clinical Studies Of Ifn‐i For Covid‐19mentioning

confidence: 80%

“…31 The efficacy of IFN-I against COVID-19 was further supported in a case study. 32 Nebulized IFN treatment for COVID-19…”

Section: Clinical Studies Of Ifn-i For Covid-19mentioning

confidence: 99%

Type I interferon: From innate response to treatment for COVID‐19

Lin¹,

Shen

2020

Pediatric Investigation

View full text Add to dashboard Cite

show abstract

“…The full-text screening of these studies led to the exclusion of 286 that did not meet the inclusion criteria. The remaining 26 studies were identified as eligible to be reviewed [ 6 , 7 , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] ]. Fig.…”

Section: Resultsmentioning

confidence: 99%

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Kubota

Kuroda

2021

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Highlights COVID-19 effects were studied in patients with comorbid neurological disorder. This review included 26 reports of comorbid neurological disorder and COVID-19. Papers were identified from the MEDLINE (PubMed) and medRxiv databases. Overall, 22.0 % of patients had severe COVID-19 course. Notably, 31.9 % of patients experienced an exacerbation of preexisting neurological symptoms.

show abstract

“…The hypothesis that certain DMT's may protect against severe complications of COVID-19, accounting for some of the favourable outcomes in reported cases, including anti-CD20 therapy (Ghajarzadeh et al, 2020;Giovannoni, 2020;Novi et al, 2020), Natalizumab (Aguirre et al, 2020) and interferon therapy (Gemcioglu et al, 2020) may require consideration in decision-making regarding DMT's as further real-world data emerges, but, based on the resources used for patient decision-making, is unlikely to have been pertinent to the relatively high proportion of patients who voiced a 'low' level of concern relating to their DMT use during the pandemic as low.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia

Seery

Nguyen

et al. 2020

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Patients with Multiple Sclerosis (MS) and on disease modifying therapies (DMTs) that can be immunosuppressive or immunomodulatory form a special group where risk of continuation of DMT needs to be taken into account with risk of contracting Covid-19. This concept can pose a degree of anxiety for patients as well as neurologists. We aimed to evaluate patient perspectives regarding the use of Natalizumab and anti-CD20 therapies (Rituximab and Ocrelizumab) in the context of the COVID-19 pandemic. Methods: cross-sectional study conducted via voluntary survey filled in by patients with MS and related disorders receiving their infusional treatment in one MS centre in Australia, exploring their concerns regarding their therapy, their therapy and COVID-19, precautions undertaken in response to the pandemic, and factors impacting their decision-making. Results: 170 patients completed the survey. Of patients on Natalizumab, the majority had either no or mild concern regarding their DMT and COVID-19, and of patients on B-cell depleting therapies, again, the majority had no or mild concern, though a slightly higher proportion had a moderate level of concern. Asked to delineate their concerns, an increased risk of contracting COVID-19 was more commonly conveyed than MS-specific factors or poor outcomes pertaining to COVID-19 if contracted, by patients in both groups. Conversely, being invited to specifically consider the possibility of contracting COVID-19 or experience a relapse of MS, almost half of the cohort rated both of equal of concern. More than half of the cohort were self-isolating more stringently than general government advice and government-related resources followed by information provided by patient's neurologist where the commonest means of information to guide decision making. Conclusions: Whilst a large proportion of patients had some concern regarding the impact of their DMT on COVID-19, whether on their risk of contracting COVID-19 or a theoretical risk for more severe disease, the overall level of concern in most cases was at most mild. Patients on B-cell depleting therapies were more inclined to express a higher level of concern. A similar concern was ascribed to a risk of a relapse or worsening MS symptoms compared to the risk of contracting COVID-19. Such attitudes may underscore a willingness of patients to continue their DMT where benefits outweigh risks during future phases of the COVID-19 pandemic.

show abstract

Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?

Cited by 22 publications

References 4 publications

Type I interferon: From innate response to treatment for COVID‐19

Type I interferon: From innate response to treatment for COVID‐19

Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review

Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia

Contact Info

Product

Resources

About